Please assess the completion status of the following clinical trial:

Trial Title: 16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, age 18-65.~* Outpatients or inpatients with a diagnosis of bipolar I, II or schizoaffective bipolar disorder, depressed phase, non-psychotic, (DSM-5 criteria, Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders Module D confirmed)~* At least mild symptom severity of depression as defined by the Clinical Global Impression for Bipolar Disorder (CGI-BP, Spearing et al. 1997) \>2.~* Bipolar I participants must be on conventional mood stabilizing treatment \[lithium, divalproex or valproate, or an atypical antipsychotic\]. Participants with a bipolar II disorder may pursue the FLAME Study as monotherapy.~* Negative urine pregnancy test.~* Participants not planning pregnancy in the near future (6 months).~* Negative urine toxicology screen (except cannabis).~* No evidence of clinically significant laboratory screening tests (complete blood count (CBC); electrolytes; thyroid stimulating hormone (TSH); creatinine/blood urea nitrogen, Aspartate Aminotransferase (AST)/ALT). Clinical laboratory evaluation within the last three months is acceptable.~Exclusion Criteria:~* Inability or unwilling to provide informed consent.~* Inability to understand English.~* Actively suicidal participants at screening or enrollment visit as defined by a response of 3 or 4 on question 4 of the Bipolar Inventory of Symptoms Scale (BISS).~* Active delusions or hallucinations defined as a score of 3 or 4 on the BISS question 40 (persecutory ideas) or 41 (delusions or hallucinations).~* Impaired insight as defined as a score of 3 or 4 on BISS question 42 (insight).~* Hypomania defined by a BISS manic subscore of ≥15.~* Axis I or II comorbidity that by referring mental health professional and/or study psychiatrist is primary need of treatment. (This will be assessed by the site principal investigator, who has \>10 years clinical experience with this population. Hospital discharge summaries and outpatient medical records may be reviewed (i.e., adequate trials of mood stabilizing treatments with minimal to no response, prominent self-injurious behavior in the absence of significant mood symptomatology, or atypical cycle patterns) to make this decision.~* Pregnant participants~* Unwilling or unable to taper any current antidepressant therapy~* Participants currently breastfeeding~* Female not practicing a reliable form of birth control (condom, intrauterine device (IUD), Depo-Provera injection)~* Due to lamotrigine pharmacokinetics, female subjects wishing to commence oral contraceptive therapy (OCT) within 3 months of enrollment date or anticipate discontinuing OCT during study (stable oral contraceptive therapy exception).~* History of active substance abuse disorder within the last 3 months (other than caffeine or cannabis)~* Participants with medical contraindications that preclude lamotrigine or fluoxetine treatment~* History of severe adverse reaction to lamotrigine and/or fluoxetine~* Current carbamazepine or oxcarbazepine treatment~* Unstable active medical illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lamotrigine (Type: ACTIVE_COMPARATOR): Subjects on this arm will be randomized to Lamotrigine.
- Fluoxetine (Type: ACTIVE_COMPARATOR): Subjects on this arm will be randomized to Fluoxetine.

Based on this trial design, predict the completion outcome and termination type (if applicable).